Crossmark

Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach

Crossref DOI link: https://doi.org/10.1016/j.farma.2024.03.008

Published Print: 2024-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Garcia Molina, Antonio http://orcid.org/0000-0003-2939-9265
License Information

Text and Data Mining valid from 2024-09-01

Text and Data Mining valid from 2024-09-01

Version of Record valid from 2024-03-18
More Information

This article is maintained by: Elsevier

Article Title: Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2024.03.008

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.